Caterina Mariotti

Curriculum Vitae

Caterina Mariotti graduated at the Medical School of the Milan University (Italy, 1987) and specialized in Neurology (1992) and then in Medical Genetics (2000). After a two-year training in molecular and cell biology at the Neuromuscular Center of the University of Southern California (USA), Dr. Mariotti started working as Neurologist at the Neurological Institute Carlo Besta (Milan, Italy, 1992).

At the Neurological Institute Carlo Besta, Dr. Mariotti holds a permanent position at the Unit of Genetics of Neurodegenerative and Metabolic Diseases where she is in charge of the outpatient clinics for Huntington Disease and leads a multidisciplinary team involved in neurological assessment and genetic counseling for patients with HD or other neurodegenerative genetic diseases.

Since 2004 Dr Caterina Mariotti became actively involved the European Huntington Disease Network (EHDN) Registry, and, since 2014, she is the PI for an Italian site of ENROLL-HD with more than 100 HD patients and premanifest subjects enrolled so far.

Research activity:

Dr Caterina Mariotti is actively involved in the organization and implementation of experimental, randomized, double-blind clinical trials in patients with Huntington Disease, and spinocerebellar ataxias, in particular Friedreich's ataxia. Interventional and

observational trials have been conducted according to GCP. Participation in the "Eurosca Clinical Studies" of the FP6 Eurosca project, and currently participating to multicenter European studies on Cerebellar Ataxias and Huntington disease. Since 2008, she is an elected Member of the Executive Committee of the Ataxia Study Group (ASG). Particularly interested on premanifest subjects and clinical studies to evaluate clinical and MRI phenotype; preclinical disease progression and possible biological markers in peripheral blood cells

Author or co-author of 135 scientific articles in peer reviewed journals, and of 6 book Chapters (**H Index**= 38)

Main incentive for the SBAC-EHDN is the possibility of sharing projects, efforts, results and learning with all members of the study group.

The personal motivation is to be an active member of the EHDN and to expand molecular and clinical studies evaluating different factors in Huntington disease pathogenesis and manifestations, and to support the efforts toward therapeutic advancements.